RT Journal Article
SR Electronic
T1 Reliability of serological tests for COVID-19: Comparison of three immunochromatography test kits for SARS-CoV-2 antibodies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.28.20140475
DO 10.1101/2020.06.28.20140475
A1 Fujigaki, Hidetsugu
A1 Takemura, Masao
A1 Osawa, Michiko
A1 Sakurai, Aki
A1 Nakamoto, Kentaro
A1 Setod, Koichi
A1 Fujita, Takashi
A1 Hata, Tadayoshi
A1 Akiyama, Hidehiko
A1 Doi, Yohei
A1 Saito, Kuniaki
YR 2020
UL http://medrxiv.org/content/early/2020/06/29/2020.06.28.20140475.abstract
AB Background Several immunochromatographic serological test kits have been developed to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibodies, but their relative performance and potential clinical utility is unclear.Methods Three commercially available serological test kits were evaluated using 99 serum samples collected from 29 patients diagnosed with coronavirus disease 2019 (COVID-19).Results The IgM antibody-positive rates of the three serological test kits for samples taken at the early stage of the disease (0–6 days after onset) were 19.0%, 23.8%, and 19.0%, respectively. The IgM antibody-positive rates over the entire period were 21.2%, 60.6%, and 15.2%, respectively. The IgG antibody-positive rates for samples taken after 13 days of onset were 100.0%, 97.6%, and 97.6%, respectively.Conclusion There were large differences among the results of the three test kits. Only few cases showed positive results for IgM in the early stage of disease and the IgM antibody-positive rates over the entire period were low, suggesting that the kits used in this study were unsuitable for diagnosis of COVID-19. The IgG antibody was positive in almost all samples after 13 days of onset, suggesting that it may be useful for determining infections in the recent past.Competing Interest StatementHidetsugu Fujigaki received immunochromatographic anti-SARS-CoV-2 antibody detection kits from Nichirei Biosciences Inc. and Shionogi & Co., Ltd. There are no other relationships or activities that could appear to have influenced this work. All other authors report no conflicts of interest relevant to this work.Funding StatementThis research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethics Committee for Clinical Research, Center for Research Promotion and Support, Fujita Health University (authorization number HM19-493).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.